Citi raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $33 from $31 and keeps a Buy rating on the shares. The firm sees the upper end of the company’s 2025 outlook as potentially achievable following the Q3 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX: